JAK Inhibitors Therapy for Rheumatoid Arthritis ：An Overview of Systematic Reviews
- VernacularTitle:JAK抑制剂治疗类风湿性关节炎的系统评价再评价
- Author:
Haikun WANG
1
;
Jie WANG
2
;
Na WU
1
;
Cunming LI
3
;
Ziwei LIN
4
;
Wei WU
1
Author Information
1. Dept. of Pharmacy，Bozhou Hospital Affiliated to Anhui University of Science and Technology/Bozhou People’s Hospital，Anhui Bozhou 236800，China
2. TCM School of Bozhou College，Anhui Bozhou 236800，China
3. Dept. of TCM，Bozhou Hospital Affiliated to Anhui University of Science and Technology/Bozhou People’s Hospital，Anhui Bozhou 236800，China
4. Dept. of General Medicine，Bozhou Hospital Affiliated to Anhui University of Science and Technology/Bozhou People’s Hospital，Anhui Bozhou 236800，China
- Publication Type:Journal Article
- Keywords:
JAK inhibitors;
Rheumatoid arthritis;
Overview of systematic reviews;
Efficacy;
Safety
- From:
China Pharmacy
2021;32(11):1362-1369
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE：To overview t he s ystematic revi ews on JAK inhibitors in the treatment of rheumatoid arthritis （RA）， and to provide evidence-based basis for the treatment of RA with these drugs. METHODS ：The Cochrane Library ，PubMed， Embase，CNKI，Wanfang database and VIP were electronically searched to collect systematic reviews of JAK inhibitors in the treatment of RA from inception to Dec. 2020. After data extraction of included systematic review ，PRISMA statement ，AMSTAR2 scale and GRADE were used to evaluate the report quality ，methodological quality and the level of evidence for outcome indicators. RESULTS ：A total of 12 systematic reviews involving 103 outcomes were included. PRISMA score of systematic reviews was between 17.5 and 22.5，and the reported quality defects were mainly reflected in scheme ，registration and other aspects. AMSTAR 2 evaluation results showed that there were 6 studies of low quality and 6 studies of very low quality ，without high-quality study and medium-quality study. GRADE assessment results for outcome indicators showed low to medium quality of evidence. The summary of evidence showed that compared to placebo ，JAK inhibitor could alleviate various indicators of RA ； compared to adalimumab ，the advantage was not obvious. JAK inhibitors did not increase the incidence of serious adverse events ， but the systematic reviews were inconsistent in their effects on the incidence of total adverse events and liver injury. CONCLUSIONS：The efficacy of JAK inhibitors in the treatment of RA has certain advantages over placebo ，but more studies are needed to demonstrate the efficacy of JAK inhibitors in the treatment of RA compared to other drugs ；the advantage of safety is uncertain.
